Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/ 10.3389/fmed.2021.547849
![](/digitum/image/email_logo.png)
![](/digitum/image/logo-facebook.png)
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Legaz Pérez, Isabel | - |
dc.contributor.author | Bernardo, María Victoria | - |
dc.contributor.author | Alfaro, Rafael | - |
dc.contributor.author | Martínez Banaclocha, Helios | - |
dc.contributor.author | Galián, Jose Antonio | - |
dc.contributor.author | Jiménez Coll, Víctor | - |
dc.contributor.author | Boix, Francisco | - |
dc.contributor.author | Mrowiec, Anna | - |
dc.contributor.author | Salmeron, Diego | - |
dc.contributor.author | Botella, Carmen | - |
dc.contributor.author | Parrado, Antonio | - |
dc.contributor.author | Moya Quiles, María Rosa | - |
dc.contributor.author | Minguela, Alfredo | - |
dc.contributor.author | Llorente, Santiago | - |
dc.contributor.author | Peña Moral, Jesús de la | - |
dc.contributor.author | Muro, Manuel | - |
dc.contributor.other | Facultades, Departamentos, Servicios y Escuelas::Departamentos de la UMU::Ciencias Sociosanitarias | - |
dc.date.accessioned | 2024-07-11T10:46:08Z | - |
dc.date.available | 2024-07-11T10:46:08Z | - |
dc.date.issued | 2021-02-17 | - |
dc.identifier.citation | Front. Med. 8:547849 | es |
dc.identifier.issn | Electronic: 2296-858X | - |
dc.identifier.uri | http://hdl.handle.net/10201/143005 | - |
dc.description | © 2021 Legaz, Bernardo, Alfaro, Martínez-Banaclocha, Galián, Jimenez-Coll, Boix, Mrowiec, Salmeron, Botella, Parrado, Moya-Quiles, Minguela, Llorente, Peña-Moral and Muro. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/. This document is the Published version of a Published Work that appeared in final form in Frontiers in Medicine. To access the final edited and published work see https://doi.org/10.3389/fmed.2021.547849 | - |
dc.description.abstract | Background: Antibody-mediated rejection (AMR) is the major cause of kidney transplant rejection. The donor-specific human leukocyte antigen (HLA) antibody (DSA) response to a renal allograft is not fully understood yet. mTOR complex has been described in the accommodation or rejection of transplants and integrates responses from a wide variety of signals. The aim of this study was to analyze the expression of the mTOR pathway genes in a large cohort of kidney transplant patients to determine its possible influence on the transplant outcome. Methods: A total of 269 kidney transplant patients monitored for DSA were studied. The patients were divided into two groups, one with recipients that had transplant rejection (+DSA/+AMR) and a second group of recipients without rejection (+DSA/–AMR and –DSA/–AMR, controls). Total RNA was extracted from kidney biopsies and reverse transcribed to cDNA. Human mTOR-PCR array technology was used to determine the expression of 84 mTOR pathway genes. STRING and REVIGO software were used to simulate gene to gene interaction and to assign a molecular function. Results: The studied groups showed a different expression of the mTOR pathway related genes. Recipients that had transplant rejection showed an over-expressed transcript (≥5-fold) of AKT1S1, DDIT4, EIF4E, HRAS, IGF1, INS, IRS1, PIK3CD, PIK3CG, PRKAG3, PRKCB (>12-fold), PRKCG, RPS6KA2, TELO2, ULK1, and VEGFC, compared with patients that did not have rejection. AKT1S1 transcripts were more expressed in +DSA/–AMR biopsies compared with +DSA/+AMR. The main molecular functions of up-regulated gene products were phosphotransferase activity, insulin-like grown factor receptor and ribonucleoside phosphate binding. The group of patients with transplant rejection also showed an under-expressed transcript (≥5-fold) of VEGFA (>15-fold), RPS6, and RHOA compared with the group without rejection. The molecular function of down-regulated gene products such as protein kinase activity and carbohydrate derivative binding proteins was also analyzed. Conclusions: We have found a higher number of over-expressed mTOR pathway genes than under-expressed ones in biopsies from rejected kidney transplants (+DSA/+AMR) with respect to controls. In addition to this, the molecular function of both types of transcripts (over/under expressed) is different. Therefore, further studies are needed to determine if variations in gene expression profiles can act as predictors of graft loss, and a better understanding of the mechanisms of action of the involved proteins would be necessary. | es |
dc.format | application/pdf | es |
dc.format.extent | 18 | es |
dc.language | eng | es |
dc.publisher | Frontiers Media | - |
dc.relation | Our work was possible thanks to the support from Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness. Grant Nos. PI15/01370 and P19/01194 and co-funding of the European Union with European Fund of Regional Development (FEDER) with the principle of A manner to build Europe. | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | mTOR | es |
dc.subject | Gene expression | es |
dc.subject | Medico-legal autopsy | es |
dc.subject | Antibody-mediated rejection | es |
dc.subject | PCR array | es |
dc.title | PCR Array technology in biopsy samples identifies up-regulated mTOR pathway genes as potential rejection biomarkers after kidney transplantation | es |
dc.type | info:eu-repo/semantics/article | es |
dc.relation.publisherversion | https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.547849/full | - |
dc.identifier.doi | https://doi.org/ 10.3389/fmed.2021.547849 | - |
Aparece en las colecciones: | Artículos: Ciencias Sociosanitarias |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
fmed-08-547849.pdf | 2,42 MB | Adobe PDF | ![]() Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons